Pharmaplius - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 7,978,345 | 5,534,218 | 3,560,449 | 3,182,481 | 2,715,989 | 5,843,285 | 15,376,630 | 16,054,931 |
| Profit before tax | 370,959 | 201,602 | 207,606 | 278,433 | 130,693 | 639,077 | 2,658,469 | 2,425,116 |
| Net profit | 315,315 | 171,356 | 176,465 | 236,668 | 111,089 | 543,215 | 2,259,699 | 2,037,084 |
| Equity | 392,849 | 449,205 | 625,671 | 682,339 | 393,428 | 936,643 | 1,544,342 | 1,591,426 |
| Liabilities | 564,222 | 166,908 | 99,295 | 51,589 | 360,163 | 256,396 | 1,068,485 | 309,059 |
| Non-current assets | 3,106 | 1,792 | 38,617 | 31,872 | 25,185 | 18,619 | 126,244 | 106,364 |
| Current assets | 953,740 | 614,094 | 685,311 | 700,741 | 726,980 | 1,172,639 | 2,484,827 | 1,792,184 |
| Total assets | 956,846 | 615,886 | 723,928 | 732,613 | 752,165 | 1,191,258 | 2,611,071 | 1,898,548 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 14,701 | 332,231 | 737,718 |
| Social insurance contributions | - | - | - | - | - | - | 11,519 | 17,217 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +35.1% | -30.6% | -35.7% | -10.6% | -14.7% | +115.1% | +163.2% | +4.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 33.0% | 27.8% | 24.4% | 32.3% | 14.8% | 45.6% | 86.5% | 107.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 80.3% | 38.1% | 28.2% | 34.7% | 28.2% | 58.0% | 146.3% | 128.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.0% | 3.1% | 5.0% | 7.4% | 4.1% | 9.3% | 14.7% | 12.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 4.6% | 3.6% | 5.8% | 8.7% | 4.8% | 10.9% | 17.3% | 15.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.4 | 0.4 | 0.2 | 0.1 | 0.9 | 0.3 | 0.7 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 3,989,173 | 2,767,109 | 1,780,225 | 1,591,241 | 1,357,995 | 2,921,643 | 4,393,323 | 4,013,733 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pharmaplius - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-26 | 2026-08-31 | 0.12 |
| 2026-08-23 | 2026-08-23 | 0.12 |
| 2026-08-19 | 2026-08-19 | 0.12 |
| 2026-07-19 | 2026-07-28 | 0.12 |
| 2026-07-16 | 2026-07-17 | 0.12 |
| 2026-06-16 | 2026-06-29 | 0.12 |
| 2026-04-20 | 2026-04-28 | 0.12 |
| 2026-03-29 | 2026-03-29 | 0.12 |
| 2026-03-17 | 2026-03-27 | 0.12 |
| 2026-02-18 | 2026-03-02 | 0.12 |
| 2026-01-16 | 2026-02-02 | 0.12 |
| 2025-12-16 | 2025-12-28 | 0.12 |
| 2025-11-18 | 2025-11-26 | 0.12 |
| 2025-10-23 | 2025-10-28 | 0.12 |
Pharmaplius - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pharmaplius, UAB (code 304377464) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €16.05M and net profit of €2.04M, with a profit margin of 12.7%. Revenue increased by 4.4% year on year and by 174.8% over two years, showing a strong expansion from €5.84M in 2023 to €15.38M in 2024 and then to the 2025 level. Net profit also rose sharply over the same period, from €543.2K in 2023 to €2.26M in 2024, before easing slightly in 2025. At the end of 2025, total assets stood at €1.90M, equity at €1.59M and liabilities at €309.1K. The balance sheet structure remained solid, with an equity ratio of 83.8% and debt-to-equity of 0.19. Asset turnover was high at 8.46x, while revenue per employee reached €4.01M and profit per employee €509.3K, indicating strong productivity. Return ratios were very high, reflecting a relatively small capital base.